WO2008055801A3 - Anti-diabetogene calcium-peptid-zusammensetzung - Google Patents

Anti-diabetogene calcium-peptid-zusammensetzung Download PDF

Info

Publication number
WO2008055801A3
WO2008055801A3 PCT/EP2007/061611 EP2007061611W WO2008055801A3 WO 2008055801 A3 WO2008055801 A3 WO 2008055801A3 EP 2007061611 W EP2007061611 W EP 2007061611W WO 2008055801 A3 WO2008055801 A3 WO 2008055801A3
Authority
WO
WIPO (PCT)
Prior art keywords
calcium
antidiabetogenic
peptide composition
diabetes
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/061611
Other languages
English (en)
French (fr)
Other versions
WO2008055801A2 (de
Inventor
Marco Sell
Dirk Bode
Guenther Sawatzki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HUMANA MILCHUNION EG
Original Assignee
HUMANA MILCHUNION EG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HUMANA MILCHUNION EG filed Critical HUMANA MILCHUNION EG
Priority to EA200970441A priority Critical patent/EA016545B1/ru
Priority to EP07847082A priority patent/EP2089046A2/de
Publication of WO2008055801A2 publication Critical patent/WO2008055801A2/de
Publication of WO2008055801A3 publication Critical patent/WO2008055801A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung einer Calcium-Peptid-Zusammensetzung erhältlich aus - mindestens einem Calciumsalz, - mindestens einem Caseinophosphopeptid (CPP) und/oder - mindestens einem Glycomakropeptid (GMP) zur Herstellung eines Mittels zur Prävention und/oder zur Behandlung von Diabetes (Typ II). Durch die Darreichung dieser Zusammensetzung ist es möglich, die Entstehung des Diabetes (Typ II) deutlich zu unterdrücken (anti-diabetogene Wirkung).
PCT/EP2007/061611 2006-11-06 2007-10-29 Anti-diabetogene calcium-peptid-zusammensetzung Ceased WO2008055801A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EA200970441A EA016545B1 (ru) 2006-11-06 2007-10-29 Применение кальций-пептидной композиции для профилактики и/или лечения сахарного диабета ii типа
EP07847082A EP2089046A2 (de) 2006-11-06 2007-10-29 Anti-diabetogene calcium-peptid-zusammensetzung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006052560.4 2006-11-06
DE102006052560A DE102006052560B4 (de) 2006-11-06 2006-11-06 Anti-diabetogene Calcium-Peptid-Zusammensetzung

Publications (2)

Publication Number Publication Date
WO2008055801A2 WO2008055801A2 (de) 2008-05-15
WO2008055801A3 true WO2008055801A3 (de) 2008-12-04

Family

ID=39148568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/061611 Ceased WO2008055801A2 (de) 2006-11-06 2007-10-29 Anti-diabetogene calcium-peptid-zusammensetzung

Country Status (5)

Country Link
EP (1) EP2089046A2 (de)
DE (1) DE102006052560B4 (de)
EA (1) EA016545B1 (de)
UA (1) UA95497C2 (de)
WO (1) WO2008055801A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1014065A2 (pt) 2009-04-03 2016-04-12 Nestec Sa melhora na promoção do crescimento compensatório saudável
CN109846901A (zh) * 2019-04-03 2019-06-07 江西安顺堂生物科技有限公司 一种促进骨骼生长、防龋齿、补充钙的制剂及制备工艺

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442132A (en) * 1978-11-13 1984-04-10 C.V. Chemie Combinatie Amsterdam C.C.A. Light bakery products for diabetics and method for the preparation of these products
WO2002017734A2 (en) * 2000-09-01 2002-03-07 The University Of Tennessee Research Corporation Materials and methods for the treatment or prevention of obesity
WO2002052954A2 (en) * 2001-01-08 2002-07-11 Societe Des Produits Nestle S.A. Nutritional composition for a bone condition
US20030008810A1 (en) * 2000-02-23 2003-01-09 Robert Portman Nutritional intervention composition for enhancing and extending satiety
CN1395870A (zh) * 2002-07-25 2003-02-12 徐佳立 多肽降糖保健食品
WO2004112766A1 (en) * 2003-06-25 2004-12-29 Hyundeok Bio & Technology Co., Ltd. Composition for lowering blood glucose
WO2007009529A2 (de) * 2005-07-19 2007-01-25 Humana Gmbh Calcium-peptid-komponente

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9927603D0 (en) * 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
US20030165574A1 (en) * 2002-03-01 2003-09-04 Ward Loren Spencer Compositions and methods for treatment of body weight conditions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442132A (en) * 1978-11-13 1984-04-10 C.V. Chemie Combinatie Amsterdam C.C.A. Light bakery products for diabetics and method for the preparation of these products
US20030008810A1 (en) * 2000-02-23 2003-01-09 Robert Portman Nutritional intervention composition for enhancing and extending satiety
WO2002017734A2 (en) * 2000-09-01 2002-03-07 The University Of Tennessee Research Corporation Materials and methods for the treatment or prevention of obesity
WO2002052954A2 (en) * 2001-01-08 2002-07-11 Societe Des Produits Nestle S.A. Nutritional composition for a bone condition
CN1395870A (zh) * 2002-07-25 2003-02-12 徐佳立 多肽降糖保健食品
WO2004112766A1 (en) * 2003-06-25 2004-12-29 Hyundeok Bio & Technology Co., Ltd. Composition for lowering blood glucose
WO2007009529A2 (de) * 2005-07-19 2007-01-25 Humana Gmbh Calcium-peptid-komponente

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200320, 2 December 2003 Derwent World Patents Index; Class 033, Page 6, AN 2003-373067, XP002499190, XU J: "Hypoglycemic health-care polypeptide food" *
ETZEL M R: "Manufacture and Use of Dairy Protein Fractions", JOURNAL OF NUTRITION 200404 US, vol. 134, no. 4, April 2004 (2004-04-01), pages 996S - 1002S, XP002499258, ISSN: 0022-3166 *
VISSER JEROEN ET AL: "Short-term dietary adjustment with a hydrolyzed casein-based diet postpones diabetes development in the diabetes-prone BB rat.", METABOLISM CLINICAL AND EXPERIMENTAL, vol. 52, no. 3, March 2003 (2003-03-01), pages 333 - 337, XP008097437, ISSN: 0026-0495 *

Also Published As

Publication number Publication date
DE102006052560A1 (de) 2008-05-08
EA016545B1 (ru) 2012-05-30
EA200970441A1 (ru) 2009-12-30
UA95497C2 (ru) 2011-08-10
WO2008055801A2 (de) 2008-05-15
DE102006052560B4 (de) 2010-01-21
EP2089046A2 (de) 2009-08-19

Similar Documents

Publication Publication Date Title
WO2008097640A8 (en) Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
WO2007139967A3 (en) Triazole compounds that modulate hsp90 activity
WO2007139955A3 (en) Triazole compounds that modulate hsp90 activity
WO2007139968A3 (en) Triazole compounds that modulate hsp90 activity
WO2009026179A3 (en) Antiinfective proanthocyanidin compounds and methods of use thereof
WO2007094819A3 (en) Triazole compounds that modulate hsp90 activity
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2010017545A3 (en) Triazole compounds that modulate hsp90 activity
WO2007150015A3 (en) Method of treatment
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
MX2010001565A (es) Compuestos triazolicos que modulan la actividad de proteina de choque termico (hsp) 90.
TW200612892A (en) Novel compounds
WO2008073332A3 (en) Creatine compositions for skin treatment
WO2008048589A3 (en) Compounds and methods for treatment of hcv
TW200732296A (en) Novel compounds
TW200745003A (en) Novel compounds
CL2007003722A1 (es) Compuestos derivados de propionamida n-sustituida por heterociclo, activadores de glucoquinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento o prevencion de la diabetes.
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2007052023A3 (en) Novel compounds
TW200731974A (en) Transdermal system for verenicline
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2006114439A3 (en) Novel nutraceutical compositions
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2007022947A3 (de) 5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07847082

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 200970441

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2007847082

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: a200905665

Country of ref document: UA